TL;DR
Turn quiet afternoons into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
An international study drawing on genetic data from nearly 2.8 million people identified 127 Alzheimer’s disease risk loci, including 48 not previously reported. The researchers also found that one method for estimating inherited risk produced higher estimates than another, but the results do not establish a definitive new heritability figure or prove that proposed drug targets will work.
An international team analyzing genetic data from nearly 2.8 million people identified 48 previously unreported Alzheimer’s disease risk loci and found evidence that a widely used approach may underestimate how much common genetic variants contribute to risk. The study, published in Nature, also linked genetic associations to immune activity in microglia and changes involving neurons, offering new research leads but not proving that any proposed target can prevent or treat the disease.
According to the study in Nature, the researchers combined data from 30 cohorts, including people diagnosed with Alzheimer’s disease, people whose parent had Alzheimer’s or dementia, and control participants. The full dataset included 109,479 people with Alzheimer’s, 74,141 proxy cases, more than 2.1 million controls and nearly 500,000 proxy controls. Proxy cases were people reporting a parent’s diagnosis; they were not counted as having Alzheimer’s themselves. The study’s effective sample size was 416,493.
The study reported 118 significant genetic loci in its multi-ancestry analysis and nine more in a European-ancestry-only analysis, for 127 overall; 48 were classified by the researchers as new. A locus is a region of the genome associated with a trait. Identifying one does not by itself establish which gene causes the association or how it affects disease.
To estimate genetic contribution, the team used SBayesRC and compared its results with estimates from linkage disequilibrium score regression, or LDSC. The study’s comparison and simulations suggested that existing methods may miss some contribution from common variants, but it did not report a single revised heritability percentage. The researchers also identified pathways involving lipids, immune activation and amyloid processing.
New Clues in Alzheimer’s Biology
The findings matter because estimates of inherited risk shape how researchers understand Alzheimer’s biology and prioritize research on risk prediction and potential treatments. Earlier twin studies have put the heritable share of susceptibility at about 60% to 80%, while prior estimates based on common genetic variants suggested a much smaller contribution to disease liability. These figures measure different aspects of genetic influence and should not be treated as interchangeable.
In the Nature study, the researchers linked genetic associations to microglia, immune cells in the brain, and to neuronal populations. Such findings can help direct further research into how inherited differences relate to brain processes. They do not mean that genetics alone determines whether someone will develop Alzheimer’s, nor do they provide an individual prediction.
The study also highlighted candidate genes including RRM2B, SYK, KEAP1, CACNA1S and AXL. These are research targets, not treatments validated by the study. The authors’ analyses can generate hypotheses for laboratory and clinical research, but establishing whether changing a target is safe and beneficial requires further testing.
Products Worth Considering
Fitbit Inspire 3 Health and Fitness Tracker Bundle
Fitbit Sense Health & Fitness Smartwatch (White/Gold, International Version)
Fitbit Versa 2 Health and Fitness Smartwatch with Heart Rate, Alexa, Music, Sleep and Swim Tracking
As an affiliate, we earn on qualifying purchases.
How the Genetic Analysis Was Built
Alzheimer’s disease is the most common type of dementia, and earlier genome-wide association studies had identified about 80 risk loci. The new analysis, published in Nature, expanded the number of reported loci by combining data across cohorts and ancestry groups, then using several methods to prioritize genes and pathways. Those methods included fine-mapping, gene-based analyses, molecular data comparisons and Mendelian randomization.
The study grouped participants by European, African, East Asian, admixed American and South Asian ancestry. However, about 91% of the effective sample was of European ancestry. The researchers noted that ancestry-specific results were less precise for groups with smaller sample sizes, limiting how confidently findings can be compared across populations.
The study’s focus on genetic associations also sits alongside existing Alzheimer’s treatment research. Current disease-modifying treatments primarily target amyloid-beta aggregates, and the study report notes that these treatments have had limited effectiveness in relieving symptoms. The genetic study did not test a treatment; its proposed targets and pathways are leads for future investigation.
Limits on Risk and Treatment Claims
The findings do not settle how much of Alzheimer’s risk is inherited. The study describes a possible underestimation by existing methods, but does not state a new, definitive percentage. Heritability estimates also describe variation in a population; they are not a measure of an individual’s certainty of developing the disease.
Some biological links remain unresolved. In the study, microglial genetic associations remained significant after adjustment for average expression differences across cell types, while neuronal associations became only nominally significant. The researchers could not determine whether observed neuronal expression patterns contribute to Alzheimer’s or occur as a consequence of neurodegeneration. No individual microglial state reached statistical significance.
The ancestry imbalance is another limitation: the large overall dataset does not mean results are equally precise for every population. And although the study highlighted five genes as potential targets, it did not test them as treatments. Earlier experimental findings cited for some targets do not establish that they would be safe or effective in people.
Further Validation and Diverse Cohorts
The study’s findings will need to be tested in larger and more representative ancestry groups, with further work to determine which genes drive each locus and how those genes affect brain cells. The study report does not announce a specific follow-up trial or timetable. The candidate targets will require additional experimental work before researchers can judge whether they merit clinical testing.
For now, the main development reported in Nature is an expanded map of Alzheimer’s genetic associations and evidence that estimates can depend on the method used. Researchers will need to replicate the results and clarify the links between inherited variation, cell activity and disease before the findings can support better risk prediction or treatment decisions.
Key Questions
What did the Alzheimer’s study find?
In a study published in Nature, researchers reported 127 genetic risk loci, including 48 not previously identified in their analysis, and found associations involving microglia, neurons and several biological pathways.
Does the study give a new percentage for inherited Alzheimer’s risk?
No revised definitive percentage is provided in the study report. The researchers found that different estimation methods may produce different results and that existing methods may underestimate the contribution of common genetic variants.
No. The study concerns population-level genetic associations and does not show that a particular variant determines an individual’s outcome.
Did researchers test new Alzheimer’s treatments?
No. The study identified possible drug targets, including SYK and AXL, but did not test these targets as treatments. More research would be needed to establish safety and effectiveness.
How representative was the study across ancestry groups?
Participants were grouped across five ancestry categories, but about 91% of the effective sample was of European ancestry. The study report says results for groups with smaller samples were less precise.
Source: news-medical.net
